Register Now for Vimpat Advantage: Step 1 of 2

Vimpat Advantage is an educational email program designed to help you take an active role in achieving seizure control. With the help of medical experts and others like you, Vimpat Advantage provides the information and support to help you get the most from your treatment.

Enroll now to start getting the seizure control you need.

Please provide the following information:

*Required information

First Name:*

Last Name:*

E-mail Address:*

Confirm E-mail Address:*

For whom are you requesting information?*

Would you like to receive our FREE EpilepsyAdvocate magazine, including tips and insights about living with epilepsy and information about treatment?

No Yes

View Magazine (4.0 mb) To do so, you need Adobe^® Reader^®.
If you do not have it, you can download it for free.

Address 1:*

Address 2:

City:*

State:*

ZIP Code:*

We respect your privacy. Please read our Privacy Policy for more information.

By providing this information, I give UCB, Inc. permission to send me information about epilepsy medicine and other similar products from UCB, Inc. and its business partners. I understand that UCB, Inc. or its business partners will not sell or transfer my name, address, e-mail address, or any other information to any other party for their own marketing use. I can remove myself from the mailing list at any time by clicking Unsubscribe on the e-Newsletters that I will receive. Please review the privacy policy of UCB, Inc.

Meet Veronica C., adding Vimpat since 2005

Over 800,000 people taking epilepsy medicine are still having seizures. Now there's hope for seizure control. Now there's Vimpat.

Indication

Vimpat^® (lacosamide) is a prescription medicine that is used with other medicines to treat partial-onset seizures in people 17 years of age and older with epilepsy.

Important Safety Information

Vimpat is generally well-tolerated, but may not be for everyone. Ask your healthcare provider if Vimpat is right for you.

Warnings and Precautions

Antiepileptic drugs, including Vimpat, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your healthcare provider right away if you have new or worsening symptoms of depression, any unusual changes in mood or behavior, or suicidal thoughts, behavior, or thoughts about self harm that you have never had before or may be worse than before. Do not stop taking Vimpat without first talking to your healthcare provider. Stopping Vimpat suddenly can cause serious problems.

Vimpat may also cause you to feel dizzy, have double vision, feel sleepy, or have problems with coordination and walking. You should not drive, operate machinery or do other dangerous activities until you know how Vimpat affects you.

Vimpat may cause you to have an irregular heartbeat or may cause you to feel faint. Call your healthcare provider if you have a fast, slow, or pounding heartbeat, shortness of breath, feel lightheaded, or if you fainted or feel like you are going to faint.

Vimpat is classified as a federally controlled substance (C-V) due to a low potential for abuse. Keep your Vimpat in a safe place and do not give it to anyone else.

In rare cases, Vimpat may cause a serious allergic reaction that may affect your skin or other parts of your body such as your liver or blood cells. Call your healthcare provider right away if you have a skin rash or hives, fever or swollen glands that do not go away, shortness of breath, swelling of the legs, yellowing of the skin or whites of the eyes, or dark urine.

Vimpat oral solution contains aspartame, a source of phenylalanine.

Common Adverse Reactions

The most common side effects with Vimpat are dizziness, headache, nausea, and double vision. To report Suspected Adverse Reactions, contact UCB, Inc. at 866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional patient information in the Patient Medication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment.

VIMPAT (lacosamide) tablets injection

Print
E-mail

*Indicates a required field

Recipient's Name*

Recipient's E-mail Address*